How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,516 results for

Vitiligo

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil. (PubMed)

Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil. Vitiligo is an acquired pigmentary disorder that affects approximately 0.5-2% of the world's population, and 25% of cases begin before 10 years of age. Although prevalent, there are few studies on the characterization of childhood vitiligo.To evaluate the clinical and epidemiological characteristics of childhood vitiligo.Transverse study conducted by reviewing data records of patients under (...) the age of 18 in which disease onset occurred before 13 years of age.Predominance of females (62%). The most common subtype was generalized vitiligo (53.8%). The average age of disease onset was 5.9 years. The most affected initial site was head/neck (44.22%). The Koebner phenomenon was present in 38.2%, emotional triggering factors in 67.0% of the patients, halo nevus in 17.4%, and associated autoimmune disease in 6.5% of the patients. Family history of vitiligo was observed in 16.9% of the patients

2019 International Journal of Dermatology

62. Clinical and Spectrophotometric Evaluation of Skin Photoadaptation in Vitiligo Patients after a Short Cycle of NB-UVB Phototherapy. (PubMed)

Clinical and Spectrophotometric Evaluation of Skin Photoadaptation in Vitiligo Patients after a Short Cycle of NB-UVB Phototherapy. The phenomenon of photoadaptation to narrow-band ultraviolet B (NB-UVB) radiation has been previously described in vitiligo and has usually been clinically measured by the assessment of the minimal erythema dose (MED) after phototesting.To assess the photoadaptive response in vitiligo and healthy skin after NB-UVB phototherapy not only clinically, but also (...) by spectrophotometry.Fourteen patients affected by generalized vitiligo underwent NB-UVB phototherapy twice weekly for 12 weeks. Before and after phototherapy, a phototesting procedure was administered on vitiligo patches and adjacent healthy skin with a solar simulated radiation (SSR). Visual assessment of the MED took place after 24 h. A spectrophotometer was used to assess the a* value and the melanin index (MI*), as signs of skin erythema and pigmentation. The photoadaptation factor (MED-PF) and the a* photoadaptation

2019 Dermatology

63. A randomized pilot study to compare hair follicle cell suspensions prepared using trypsin alone versus trypsin in combination with collagenase type I for transplantation in vitiligo. (PubMed)

A randomized pilot study to compare hair follicle cell suspensions prepared using trypsin alone versus trypsin in combination with collagenase type I for transplantation in vitiligo. Noncultured extracted hair follicle outer root sheath cell suspension (NC-EHF-ORS-CS) is an upcoming surgical technique to treat stable vitiligo. Conventionally it employs trypsin to tap the hair follicle (HF) reservoir for autologous melanocytes and their precursors for transplantation. However, a perifollicular (...) with stable vitiligo. Three similar patches were randomized into three parallel treatment arms [(A) trypsin plus collagenase, (B) trypsin alone and (C) dermabrasion with vehicle alone]. Each patient's HF sample was divided and digested by the two methods, and transplanted as suspensions onto dermabraded patches, while a third dermabraded patch received the vehicle only. Suspensions were sent for laboratory analysis. Repigmentation was assessed over a follow-up of 6 months.There was a significant increase

2019 Clinical & Experimental Dermatology

64. Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. (PubMed)

Evaluation of the effect of combined intralesional injection of prostaglandin F2α with narrow band UVB phototherapy in treatment of resistant cases of vitiligo. Background: Vitiligo is a chronic cutaneous disease characterized with hypopigmented patches that leave psychological impact on the patients. There is increasing need for new treatment modalities to shorten the duration of treatment of vitiligo with the least side effects. Objective: To explore the effect of intralesional injection (...) of prostaglandin F2α on the outcome of narrow band ultraviolet rays B (NBUVB) for patients with stable vitiligo. Patients and methods: The study included 27 stable vitiligo patients with overall symmetrical lesions. For each patient, one patch was treated with NBUVB alone (control side), while another symmetrical patch was treated with combined intralesional injection of prostaglandin F2α with NBUVB therapy, weekly for 3 months. Results: There was statistically significant improvement in the repigmentation

2019 Journal of Dermatological Treatment

65. Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. (PubMed)

Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. Vitiligo is associated with medical conditions, primarily autoimmune disorders; however, only a few studies in the United States have investigated these associations.Our purpose was to investigate the diseases associated with vitiligo in the New York, New York, population and evaluate if these associations differ by race/ethnicity and sex.In this retrospective study, we analyzed data (...) collected from the medical records of 1487 vitiligo patients seen at New York University during a 10-year period.Vitiligo patients had a statistically significant higher prevalence of hypothyroidism, multiple sclerosis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, seronegative arthritis, pernicious anemia, myasthenia gravis, inflammatory bowel disease, lymphoma, and systemic lupus erythematosus. Rates of comorbid autoimmune diseases varied by race and sex.Medical charts did

2019 Journal of American Academy of Dermatology

66. Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors. (PubMed)

Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors. Current therapies for metastatic melanoma (anti-PD1 and BRAF/MEK inhibitors) can cause drug-induced vitiligo. The aim of this study is to dermatologically define and histologically characterize this new type of vitiligo, and assess the clinical course of the disease. Fourteen patients with metastatic melanoma treated with immune or targeted therapy were (...) included in a dataset evaluating clinical data, vitiligo description and histopathological features. Vitiligo-like lesions occurred after a mean of 7.5 months from the start of the therapies (range 1-42 months), with a prevalence of the non-segmental variant (71.4%). Fifty percent of patients showed a clinical response (4 complete response and 3 partial response), 35.7% had stable disease, and one patient died after disease progression. Median survival from the start of the therapies was 32.5 months

2019 Acta Dermato-Venereologica

67. Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo. (PubMed)

Open Label Pilot Study of 2% Tofacitinib for the Treatment of Refractory Vitiligo. Treatment options for vitiligo are limited and many cases remain refractory to first and second line treatments. Interferon-gamma signaling mediated by Janus kinase (JAK) has been implicated in the pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a potent JAK1/3 inhibitor, has been effective in treating vitiligo in case reports,2 however, it is associated with infections, malignancies

2019 British Journal of Dermatology

68. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment. (PubMed)

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment. is missing (Short communication).

2019 Acta Dermato-Venereologica

69. Family Clustering of Autoimmune Vitiligo Results Principally from Polygenic Inheritance of Common Risk Alleles. (PubMed)

Family Clustering of Autoimmune Vitiligo Results Principally from Polygenic Inheritance of Common Risk Alleles. Vitiligo is an autoimmune disease that results in patches of depigmented skin and hair. Previous genome-wide association studies (GWASs) of vitiligo have identified 50 susceptibility loci. Variants at the associated loci are generally common and have individually small effects on risk. Most vitiligo cases are "simplex," where there is no family history of vitiligo, though occasional (...) family clustering of vitiligo occurs, and some "multiplex" families report numerous close affected relatives. Here, we investigate whether simplex and multiplex vitiligo comprise different disease subtypes with different underlying genetic etiologies. We developed and compared the performance of several different vitiligo polygenic risk scores derived from GWAS data. By using the best-performing risk score, we find increased polygenic burden of risk alleles identified by GWAS in multiplex vitiligo

2019 American Journal of Human Genetics

70. Helen Tuckwood: Living with vitiligo

Helen Tuckwood: Living with vitiligo Helen Tuckwood: Living with vitiligo - The BMJ ---> I first noticed two patches of white skin about 10 years ago, when I was 47 years old. The patches were on the inside top of my thighs, symmetrical to each other. I had just returned from a holiday abroad and the white patches stood out. At first they didn’t really bother me because the patches were hidden, but after a time, when they started to spread, I decided to investigate the cause. I read about (...) the possible causes on the internet and concluded that it might be vitiligo. I later visited my doctor who confirmed that this diagnosis was correct. My doctor explained that there wasn’t really any treatment that could halt the progress of this condition. Light treatment was an option, but it would mean visits to the hospital two or three times a week for phototherapy. I can’t remember what other treatments were offered, but I remember thinking that there was no guarantee they would halt the vitiligo

2017 The BMJ Blog

71. Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo. (PubMed)

Combination therapy of orally administered glycyrrhizin and UVB improved active-stage generalized vitiligo. Glycyrrhizin has been used clinically for several years due to its beneficial effect on immunoglobulin E (IgE)-induced allergic diseases, alopecia areata and psoriasis. In this study, glycyrrhizin, ultraviolet B light (UVB) or a combination of both were used to treat active-stage generalized vitiligo. One hundred and forty-four patients between the ages of 3 and 48 years were divided (...) into three groups: group A received oral compound glycyrrhizin (OCG); group B received UVB applications twice weekly, and group C received OCG+UVB. Follow-ups were performed at 2, 4, and 6 months after the treatment was initiated. The Vitiligo Area Scoring Index (VASI) and the Vitiligo Disease Activity (VIDA) instrument were used to assess the affected body surface, at each follow-up. Results showed that 77.1, 75.0 and 87.5% in groups A, B and C, respectively, presented repigmentation of lesions

Full Text available with Trip Pro

2016 Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas

72. Liver X Receptor-α polymorphisms (rs11039155 and rs2279238) are associated with susceptibility to vitiligo (PubMed)

Liver X Receptor-α polymorphisms (rs11039155 and rs2279238) are associated with susceptibility to vitiligo Vitiligo is a complex genetic skin depigmentation disorder caused by the destruction of melanocyte from the lesional site. Liver X Receptor-α (LXR-α) expression is upregulated in the melanocytes from perilesional skin as compared to the normal skin of vitiligo patient suggesting its involvement in vitiligo pathogenesis. Polymorphisms in LXR-α have been associated with several diseases (...) including cardiovascular disease, polycystic ovary syndrome, cancer, inflammatory bowel disease and diabetes. In this study, for the first time, we have investigated the association of LXR-α gene polymorphisms and risk of vitiligo. Sixty six vitiligo patients and 75 matched healthy control subjects who did not have any history of vitiligo or any other autoimmune disorder were recruited. The DNA isolated from patients and healthy controls was genotyped by polymerase chain reaction-restriction fragment

Full Text available with Trip Pro

2016 Meta gene

73. The effect of topical piperine combined with narrowband UVB on vitiligo treatment: A clinical trial study. (PubMed)

The effect of topical piperine combined with narrowband UVB on vitiligo treatment: A clinical trial study. Vitiligo is the most common acquired hypopigmentary disease in the community. Piperine as an herbal extract derived from black pepper has strong impact on the melanocyte proliferation and adverse side effects less than synthetic drugs such as corticosteroids. For the first time, this study was aimed to evaluate the effect of topical piperine combined with narrowband ultraviolet B (NB-UVB (...) ) on vitiligo treatment. In this double-blind clinical trial, 63 patients with facial vitiligo were randomly divided into 2 groups: treated with piperine (case) and placebo (control). Also, both groups received NB-UVB phototherapy every other day for 3 months. In the case group, 10 patients have burning sensation on their skin areas (p value = .002). Also, redness of the treated areas was observed in 6 patients (p value = .028). Both side effects were temporary. Regarding repigmentation at time intervals

2018 Phytotherapy research : PTR

74. Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: A prospective, randomized comparative trial. (PubMed)

Combined treatment with fractional carbon dioxide laser, autologous platelet-rich plasma, and narrow band ultraviolet B for vitiligo in different body sites: A prospective, randomized comparative trial. Multiple treatment options are introduced in treatment of vitiligo but the response is unsatisfactory.In this prospective, randomized, comparative trial, we studied the effect of combined treatment with fractional carbon dioxide (CO2 ) laser, platelet-rich plasma (PRP) injection, and narrowband (...) ultraviolet B (NB-UVB) for stable nonsegmental vitiligo regarding repigmentation grade, patient's satisfaction, and side effects.Eighty adult patients with localized nonsegmental vitiligo were enrolled in this study. The patients were randomly categorized to receive 4 lines of treatment; fractional CO2 laser, PRP, combined fractional CO2 laser and PRP, and combined fractional CO2 laser and NB-UVB. The treatment period was 2 months. Patients were clinically evaluated 3 months after the last treatment

2018 Journal of cosmetic dermatology

75. Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol. (PubMed)

Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol. Vitiligo is a pigmentary disorder of skin affecting at least 1% of the world population of all races in both sexes. Its importance is mainly due to subsequent social and psychological problems rather than clinical complications. Various treatment choices are available for vitiligo; however, laser-based courses have shown to give more acceptable results.The aim of this trial was to evaluate the efficacy (...) of Er:YAG laser as a supplementary medicine to topical 5FU and clobetasol in vitiligo patients.Two comparable vitiligo patches from 38 eligible patients were randomized to receive topical 5FU and clobetasol in control group and additional Er:YAG laser in intervention group. Major outcomes of interest were the size of patch and pigmentation score at randomization and 2 and 4 months after therapy.Final sample included 18 (47%) male patients and age of 35.66±8.04. The performance Er:YAG group was superior

2018 Journal of cosmetic dermatology

76. Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial. (PubMed)

Efficacy of oral cholecalciferol on rhododendrol-induced vitiligo: A blinded randomized clinical trial. Rhododendrol (RD), 4-(4-hydroxyphenyl)-2-butanol, inhibits melanin synthesis and has been used for skin-whitening cosmetic products. RD has been very effective in lightening skin pigmentation, but some persons have developed so-called RD vitiligo, in which vitiligo starts on the face, neck and hands where topical RD has been applied and even extended over skin areas where RD has not been (...) applied. RD vitiligo lesions in some patients have lasted for years and have been resistant to conventional vitiligo treatments. We examined the effects of cholecalciferol on RD vitiligo in a blinded randomized clinical trial. Forty-eight female RD vitiligo patients were recruited for the trial and were randomized into two groups: the vitamin D (VD)-intervention group that received daily 5000 IU cholecalciferol for 5 months and the control group. Three blinded investigators scored vitiligo improvement

2018 The Journal of dermatology

77. Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. (PubMed)

Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. 29617528 2018 06 13 2168-6084 154 6 2018 Jun 01 JAMA dermatology JAMA Dermatol Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial. 725-726 10.1001/jamadermatol.2017.6401 Nguyen Sophie S Department of Dermatology, Université Côte d'Azur, Centre Hospitalier Universitaire Nice, Nice, France. Chuah Sai Yee SY National

2018 JAMA dermatology

78. Preliminary study on the treatment of vitiligo with carbon dioxide fractional laser together with tacrolimus. (PubMed)

Preliminary study on the treatment of vitiligo with carbon dioxide fractional laser together with tacrolimus. Tacrolimus is a conventional medication for the treatment of vitiligo, but the effect of a single medication is limited.This paper aims at observing the effects, adverse responses, and repigmentation results of the joint treatment of vitiligo by Carbon dioxide (CO2 ) fractional laser together with tacrolimus.Forty-five patients with vitiligo were randomly divided into two groups (...) assessments. When the treatment time was increased, the efficacy was also improved, and the repigmentation in the T group occured in three ways: perifollicular repigmentation, marginal repigmentation and diffuse repigmentation. There were three cases of isomorphic responses (2 cases in the rapid progression stage, one case in the progression stage), and 1 case formed scarring on the neck in the T group.The treatment of vitiligo by CO2 fractional laser together with tacrolimus is significantly effective

2018 Lasers in surgery and medicine

79. Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. (PubMed)

Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. 28300320 2018 08 20 2018 08 20 1365-2230 42 3 2017 Apr Clinical and experimental dermatology Clin. Exp. Dermatol. Improvement in moderate to severe vitiligo using a novel combination of 308 nm excimer laser and a surgical needling technique. 363-366 10.1111/ced.13056 BinSheikhan S S Department of Dermatology, Zayed Military Hospital, Abu Dhabi, United Arab Emirates (...) . Al Abadie M M http://orcid.org/0000-0002-0727-4632 Department of Dermatology, Royal Wolverhampton NHS Trust, Wolverhampton, and Medical School, Birmingham, West Midlands, UK. eng Journal Article Randomized Controlled Trial England Clin Exp Dermatol 7606847 0307-6938 IM Adolescent Adult Aged Combined Modality Therapy Female Humans Lasers, Excimer therapeutic use Low-Level Light Therapy adverse effects instrumentation Male Middle Aged Needles Vitiligo radiotherapy surgery Young Adult 2016 04 06

2018 Clinical and experimental dermatology

80. Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial. (PubMed)

Use of platelet-rich plasma to suspend noncultured epidermal cell suspension improves repigmentation after autologous transplantation in stable vitiligo: a double-blind randomized controlled trial. Noncultured epidermal cell suspension (NCES) is an effective surgical modality for stable vitiligo which involves transplantation of the basal layer of epidermal cells onto the dermabraded vitiliginous patch. Platelet-rich plasma (PRP) has growth factors which may stimulate melanocyte migration (...) and proliferation of keratinocytes and fibroblasts. The objective of this study was to compare the extent of repigmentation achieved by transplantation of NCES suspended in PRP with that of NCES suspended in phosphate buffered saline (PBS).Twenty-one patients of stable vitiligo with at least two lesions of comparable size were included. The two vitiligo patches were randomized to receive NCES suspended in PRP or PBS. Postoperatively after 1 week, patients were given heliotherapy for 15 minutes daily.At 6 months

2018 International Journal of Dermatology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>